NervGen to host inaugural R&D Day webcast on NVG-291 program

• NervGen scheduled an inaugural R&D Day webcast for Sept. 30, 2026, starting at 10 a.m. ET.
• The session will outline the NVG-291 program, including clinical data to date and the design of the Phase 3 RESTORE registrational study.
• Registration is available via the company website at https://www.nervgen.com.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090730PRIMZONEFULLFEED9823062) on September 09, 2026, and is solely responsible for the information contained therein.